Medtronic PLC (LTS:0Y6X)
$ 81.63 1.13 (1.41%) Market Cap: 104.56 Bil Enterprise Value: 125.12 Bil PE Ratio: 25.24 PB Ratio: 2.18 GF Score: 78/100

Medtronic PLC Neuromodulation Business Investor and Analyst Call Transcript

Oct 04, 2021 / 05:00PM GMT
Release Date Price: $124.64 (-1.71%)
Ryan Weispfenning
Medtronic plc - VP of IR

Okay. I think we're going to -- it's time to get started. So hello, everyone. I'm Ryan Weispfenning, Vice President and Head of Investor Relations at Medtronic. Thank you for joining us for our Medtronic General Manager Call Series. Today marks the second episode this calendar year and the fifth since we initiated these in late 2019.

We're excited to host the second episode here of our GM Call Series. And we've got a full pipeline of innovative products and ongoing launches that we intend to highlight with these calls and give you an opportunity to hear from and interact with the presidents and general managers who are running these large businesses at Medtronic.

For today's event, we're pleased to feature our Neuromodulation business, which is in our Neuroscience portfolio. I'm going to invite each of our Neuromod leaders to turn on their videos one by one in a moment. But for now, I'll introduce them by name and title. You can see their pictures here on the slide.

So joining me today is Dave Anderson, President of Neuromodulation

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot